Thrombosis

New Arixtra indications: Acute deep venous thrombosis, acute pulmonary embolism

Published in Medical Letter on the CDC and FDA, July 4th, 2004

Sanofi-Synthelabo announced that the synthetic, selective factor Xa inhibitor Arixtra (fondaparinux sodium) has been approved by the U.S. Food and Drug Administration (FDA) for two new indications:

1) the treatment of acute deep venous thrombosis (DVT) when administered in conjunction with warfarin sodium, and

2) the treatment of acute pulmonary embolism (PE) when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital

Arixtra is already indicated in the United-States for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing hip fracture...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-07-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry